Meeting
2013 ASCO Annual Meeting
Prognostic significance of reduction rate of Ki-67 after neoadjuvant chemotherapy in breast cancer patients with non-pCR.
Authors
Nobuaki Matsubara
National Cancer Center Hospital East, Chiba, Japan
Nobuaki Matsubara , Hirofumi Mukai , Yoichi Naito , Ako Hosono , Kuniaki Itoh , Satoshi Fujii , Kimiyasu Yoneyama , Noriaki Wada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Local Therapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1113)
DOI
10.1200/jco.2013.31.15_suppl.1113
Abstract #
1113
Poster Bd #
30D
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.
First Author: Oleg Gluz
Poster
2013 Breast Cancer Symposium
Biomarkers predictive for pathologic response to neoadjuvant docetaxel/cyclophosphamide chemotherapy in primary breast cancer.
First Author: Kazuhiro Shimada
Poster
2013 ASCO Annual Meeting
Molecular biomarkers as predictive factors of pCR for early triple-negative breast cancer.
First Author: Ismael Ghanem
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah